Abstract
Canakinumab (CAN), a selective, human anti-IL-1β monoclonal antibody is approved for SJIA in over 30 countries. Efficacy and safety of CAN over 12 weeks have been demonstrated in 2 phase III trials [1]. Out of these trials >60% of the pts received a previous biologic and were switched to CAN due to lack of efficacy or for safety reasons, and may be more refractory to another biologic therapy.
Highlights
Canakinumab (CAN), a selective, human anti-IL-1b monoclonal antibody is approved for SJIA in over 30 countries
Higher aACR-JIA 70 and 90 response rates were achieved in BN vs. BE pts ( Week 2: aACR-JIA 70: 67% vs 52%; aACR-JIA 90: 36% vs 37%; Week 12: aACR-JIA 70: 70% vs 55%; aACR-JIA 90: 61% vs 42%). aACR-JIA 70 and 90 response rates were similar in pts previously exposed to ANA vs those not exposed to ANA at 12 weeks
Compared to pts who discontinued ANA due to lack of efficacy, there was a trend towards higher aACRJIA 70 and 90 response rates at Week 12 in pts who stopped ANA for other reasons
Summary
Canakinumab (CAN), a selective, human anti-IL-1b monoclonal antibody is approved for SJIA in over 30 countries. Out of these trials >60% of the pts received a previous biologic and were switched to CAN due to lack of efficacy or for safety reasons, and may be more refractory to another biologic therapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
